Ignite Creation Date:
2024-05-06 @ 5:51 PM
Last Modification Date:
2024-10-26 @ 2:36 PM
Study NCT ID:
NCT05452798
Status:
COMPLETED
Last Update Posted:
2024-03-01
First Post:
2022-07-06
Brief Title:
A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HRHER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HRHER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark
Status:
COMPLETED
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective is to retrospectively describe and assess clinical and demographical characteristics treatment patterns in a real-world RW setting of patients with HRHER2- hormone receptor positivehuman epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer receiving palbociclib in combination treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None